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A B S T R A C TObjective: To assess the feasibility and value of simulating whole
disease and treatment pathways within a single model to provide a
common economic basis for informing resource allocation decisions.
Methods: A patient-level simulation model was developed with the
intention of being capable of evaluating multiple topics within National
Institute for Health and Clinical Excellence’s colorectal cancer clinical
guideline. The model simulates disease and treatment pathways from
preclinical disease through to detection, diagnosis, adjuvant/neoadju-
vant treatments, follow-up, curative/palliative treatments for metasta-
ses, supportive care, and eventual death. The model parameters were
informed by meta-analyses, randomized trials, observational studies,
health utility studies, audit data, costing sources, and expert opinion.
Unobservable natural history parameters were calibrated against exter-
nal data using Bayesian Markov chain Monte Carlo methods. Economic
analysis was undertaken using conventional cost-utility decision
rules within each guideline topic and constrained maximization rules
across multiple topics. Results: Under usual processes for guidelinesee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.02.012
den@sheffield.ac.uk.
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eld, Regent Court, 30 Regent Street, Sheffield S1 4development, piecewise economic modeling would have been used to
evaluate between one and three topics. The Whole Disease Model was
capable of evaluating 11 of 15 guideline topics, ranging from alternative
diagnostic technologies through to treatments for metastatic disease.
The constrained maximization analysis identified a configuration of
colorectal services that is expected to maximize quality-adjusted life-
year gains without exceeding current expenditure levels. Conclusions:
This study indicates that Whole Disease Model development is feasible
and can allow for the economic analysis of most interventions across a
disease service within a consistent conceptual and mathematical
infrastructure. This disease-level modeling approach may be of partic-
ular value in providing an economic basis to support other clinical
guidelines.
Keywords: colorectal cancer, economic analysis, simulation models.
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This article concerns the development of Whole Disease Models,
a system-level modeling approach that involves modeling events,
costs, and outcomes across whole pathways from preclinical
disease through to diagnosis and referral, adjuvant treatment,
follow-up, potential recurrence, palliative treatment, end-of-life
care, and eventual death within a single consistent model. This
broader model boundary, together with a high level of depth in
the representation of disease and treatment events, enables such
models to provide a platform for the economic analysis of
virtually any type of health intervention used at any point within
the pathway. Recently, Tappenden et al. [1] set out a methodo-
logical framework for developing Whole Disease Models and
outlined the circumstances under which the benefits of using
such models may outweigh the costs of developing them. One
such scenario is whereby a large set of decisions must be
made across a disease pathway. In the United Kingdom, this isa common situation in the context of clinical guideline
development.
Clinical guidelines are developed across the world with the
intention of making recommendations for practice that will
improve health outcomes for patients suffering from a particular
disease or condition. Guideline development typically involves
the prioritization of several discrete topics or research questions,
and the formulation of clinical recommendations within each
topic on consideration of the strengths and weaknesses of the
available evidence. Clinical guidelines developed by the National
Institute for Health and Clinical Excellence (NICE) in England and
Wales differ from those produced elsewhere in that the recom-
mendations of NICE’s Guideline Development Groups (GDGs) are
intended to be explicitly underpinned by considerations of cost-
effectiveness [2]. The problems of formulating guidelines that
adhere to a rigorous economic framework have been recognized
for some time. Wailoo et al. [2] highlight a conflict between the
responsibility of the GDG to promote the welfare of the individualSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
and Decision Science, School of Health and Related Research,
DA, UK.
Table 1 – Guideline topics, options, and methods for modifying the baseline model.
Topic Clinical topic area Option under assessment Modification to the baseline
Whole Disease Model
A Diagnostic modalities for patients
with symptoms of colorectal
cancer
(A1) COL plus biopsy (baseline); (A2) CTC;
(A3) FSIG þ COL; (A4) FSIG followed by
BE
Patients routed to alternative initial/
secondary diagnostic test work centers,
each of which differs in terms of
operating characteristics, risks, and
costs. No additional evidence required
beyond that used to develop the
baseline model
B Tumor staging for colorectal cancer Options include CT, CT/PET, MR, EUS, and
DRE
Topic not evaluated using the Whole
Disease Model
C Curative treatment for patients with
stage I or polyp cancer
(C1) radical resection (baseline); (C2) local
resection including TEMS plus
polypectomy; (C3) contact RT
DFS HR for TEMS vs. radical resection
applied to baseline rectal cancer Dukes’
A DFS curve. TEMS cost derived from
Maslekar et al. [52]. No evidence was
identified for contact RT
D Treatment for patients presenting
with emergency symptoms
(D1) CT scan (baseline); (D2) no CT scan;
(D3) stenting as a bridge to surgery
(baseline); (D4) immediate surgery
For options D2 and D4, stenting services
and prior CT are not assumed to be
available; hence, all patients with
obstruction are routed to emergency
surgery
E The sequence of local and systemic
treatments in patients presenting
with locally advanced colorectal
cancer
(E1) current local/systemic treatments
(baseline); (E2) preop CRT (colon); (E3)
surgery alone (colon); (E4) preop RT
(rectal); (E5) preop CRT (rectal); (E6)
preop chemotherapy (rectal); (E7)
surgery alone (rectal)
For option E4, R0-predicted patients are
routed to preop RT. For option E5, R0-
predicted patients are routed to preop
RT and a hazard ratio of 0.84 (95% CI
0.78–1.13) for preop CRT vs. RT was
applied to the preop RT DFS curve for
patients with Dukes’ B/C cancer [53],
and a cost of 2  5 d of 5-FU/FA was
applied. For option E7, patients are
routed to receive selective postop CRT.
No evidence identified for options E2,
E3, or E6.
F Local/systemic treatment
sequences in patients with
synchronous metastases
(F1) staged resection (baseline); (F2)
simultaneous resection; (F3)
chemotherapy
Option F2 assumes shorter length of stay;
hence, costs of surgery reduced by
£2485 per patient with no difference in
clinical outcomes. Option F3 was not
evaluated because of a lack of evidence
G Effectiveness of a) short course RT
and b) CRT for rectal cancer
(G1) current mix of preop/postop
treatments (baseline); (G2) preop RT;
(G3) preop CRT
Option G2 routes R0-predicted patients to
preop RT. Option G3 routes R0-predicted
patients to preop RT and applies a
hazard ratio of 0.84 for preop CRT vs. RT
for Dukes B/C patients. Cost of 5-FU/FA
for 10 days was also applied
H Adjuvant chemotherapy after
surgery for rectal cancer
(H1) current use of adjuvant
chemotherapy (baseline); (H2) 5-FU/FA
for all patients; (H3) no adjuvant
chemotherapy
Option H2 DFS curves for preop RT and
selective postop CRT adjusted by hazard
ratio of 0.80 (95% CI 0.73–0.88). The
probability that a Dukes’ B/C rectal
cancer patient receives adjuvant
chemotherapy was set to 1.0. Option H3
was not run because it is confounded by
the use of chemotherapy in the baseline
time-to-event curves
I Adjuvant chemotherapy for high-
risk stage II colon cancer
(I1) 5-FU/FA-based chemotherapy
(baseline); (I2) no adjuvant
chemotherapy.
Option I2 assumes all patients with
Dukes’ B colon cancer routed to no
chemotherapy, thereby assuming lower
DFS and zero adjuvant chemo cost
J Ablation, surgery, regional therapy,
and systemic therapy for
apparently incurable metastatic
disease
(J1) palliative chemotherapy (baseline); (J2)
HAI; (J3) best supportive care
Option J2 modeled by applying a hazard
ratio from Mocellin et al. [54]. Cost
estimates for HAI were drawn from
Durand-Zeleski et al. [55]
K/L Clinical indications for
metastasectomy of the liver/lung
Competing options not defined Topic not evaluated using the Whole
Disease Model
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Table 1 – continued
Topic Clinical topic area Option under assessment Modification to the baseline
Whole Disease Model
M Chemotherapy for patients with
advanced and metastatic disease
(M1) Current mix of palliative
chemotherapies; (M2–M22) various
chemotherapy sequences. A broader set
of options was evaluated than those
defined in the scope
Different OS and PFS hazard ratios applied
to baseline model based on a network
meta-analysis [56]. Costs applied
according to treatment duration.
Different downstaging success rates
were applied according to each regimen
N Follow-up after potentially curative
treatment for colorectal cancer
(N1) Intensive follow-up; (N2) Relaxed
follow-up
Follow-up test costs reduced by 62% based
on a previous economic analysis [57].
The probability that a patient with
metastatic recurrence is initially
operable or potentially operable was
multiplied by 0.50 based on Jeffery et al.
[58]
O Colorectal-specific support for
diagnosed patients
Competing options not defined Topic not evaluated using the Whole
Disease Model
BE, barium enema; COL, colonoscopy; CRT, chemoradiation; CT, computed tomography; CTC, computed tomography colonography; DFS,
disease-free survival; EUS, endoscopic ultrasound; 5-FU/FA, 5-fluorouracil plus folinic acid; FSIG, flexible sigmoidoscopy; HAI, hepatic arterial
infusion; HR, hazard ratio; MR, magnetic resonance; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival;
postop, postoperative; preop, preoperative; RT, radiotherapy; TEMS, transanal endoscopic microsurgery.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 4 2 – 5 5 3544patient and their responsibility to other patients and society to
promote cost-effectiveness within a resource-constrained health
system. While each recommendation will have an impact on the
allocation of scarce resources, these implications are not always
formally considered.
Within each NICE clinical guideline, 15 to 20 topics are
prioritized for review and the GDG makes best practice recom-
mendations within each topic [3]. Owing to limited time and
resource, the economic implications of between one and three
topics are typically examined through the development of a de
novo economic model. For the remaining topics, recommenda-
tions may be reliant on published analyses. Existing economic
studies, however, tend to have limited applicability to the
research questions addressed by the GDG, and sometimes no
relevant published evidence is available. This results in a sit-
uation whereby the economic implications of service change are
only partially addressed. Consequently, there remains a possibil-
ity that health improvements arising from the use of formal
economic analysis within certain topics are negated by ineffi-
ciencies arising from other guideline recommendations that have
not been subjected to a similar level of rigor.
The hypothesis underlying this study is that Whole Disease
Modeling can provide a more coherent and useful platform for the
economic evaluation of health technologies within a given dis-
ease area as compared against conventional piecewise economic
evaluation. To test this hypothesis, this article details the develop-
ment of a colorectal cancer Whole Disease Model to examine the
potential value of the approach, using the NICE clinical guideline
for the diagnosis and management of colorectal cancer [4] as a
case study. From a methodological perspective, the model is
simply intended to assess the feasibility and value of the
approach, while from an applied viewpoint, it is intended to
provide a comprehensive infrastructure for informing resource
allocation decisions across the entire colorectal pathway. Because
of the process constraints of the development of the colorectal
cancer guideline, the Whole Disease Model was not used to inform
guideline recommendations, and conventional economic analysis
was undertaken by another academic center. This parallel model
development activity thus creates a unique natural experiment
whereby the value of Whole Disease Modeling can be directly
compared against conventional piecewise economic evaluation.Methods
The development of the colorectal cancer Whole Disease Model
followed the methodological framework set out by Tappenden
et al. [1] based on five main process elements: 1) understanding
the decision problem, 2) model conceptualization and design, 3)
implementation modeling, 4) model checking, and 5) engaging
with the decision.
Decision Problem Scope
Fifteen topics were identified by stakeholders for consideration
within the colorectal cancer guideline (see the left-hand columns
in Table 1). These topics span most of the breadth of the color-
ectal pathway, ranging from the use of alternative diagnostic
modalities to treatments of metastatic disease. Population
screening and the management of increased-risk groups were
excluded from the remit of the guideline. The presence of
screening further upstream in the colorectal cancer service,
however, may shift the case-mix of patients at diagnosis, thereby
influencing the costs and outcomes of downstream services.
Consequently, the scope of the Whole Disease Model is broader
because it includes both a natural history model and a population
screening component.
Conceptual Models of Disease and Service Pathways for
Colorectal Cancer
Detailed problem-oriented conceptual models describing color-
ectal cancer disease progression and service pathways were
developed by using methods described in Tappenden et al. [1]
and Tappenden [5]. The first conceptual ‘‘disease logic’’ model
describes the natural history of colorectal cancer and differential
prognosis conditional on disease stage. The second conceptual
‘‘service pathways’’ model describes the main pathways
for colorectal cancer services from detection and diagnosis
through to treatments for early disease, follow-up, treatments
for recurrence, and end-of-life care. These problem-oriented
conceptual models were developed through the examination of
cancer service guidance, local treatment protocols, NICE guid-
ance, and considerable clinical input. These conceptual models
Fig. 1 – Structure of the colorectal cancer Whole Disease Model. Key disease events/clinical intent shown in italics. APER,
abdominoperineal resection; AR, anterior resection; BE, barium enema; Cap, capecitabine; CEA, carcinoembryonic antigen;
Cet, cetuximab; COL, colonoscopy; CRT, chemoradiation; CT, computed tomography; EMR, endoscopic mucosal resection; 5-
FU/FA, 5-fluorouracil plus folinic acid; FSIG, flexible sigmoidoscopy; HNPCC, hereditary nonpolyposis colorectal cancer; Ir,
irinotecan; LCRT, long course radiotherapy; MRI, magnetic resonance imaging; Ox, oxaliplatin; SCRT, short course
radiotherapy; WSE, water-soluble enema.
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ways; they do not make assertions about the structure of the
implemented model. Because of the complexity of these con-
ceptual models, they are not presented here but are available in
full elsewhere [6]. A third ‘‘design-oriented’’ conceptual model
(Fig. 1) was developed to draw together interrelationships
between the disease and service pathways. This latter model
was used as a basis for considering alternative model designs,
anticipated evidence requirements, and determining the appro-
priate level of depth within each part of the model.
The Implemented Colorectal Cancer Whole Disease Model
Economic perspective, costs, and health outcomes
The model was implemented as a probabilistic next-event patient-
level simulation by using SIMUL8 based on the conceptual model-
ing exercise [6]. The economic analysis follows NICE’s Reference
Case [7] and includes those costs borne by the National Health
Service (NHS) and Personal Social Services and benefits accrued by
NHS patients. Costs are valued at 2011 prices. In line with current
recommendations [7], costs and health outcomes are discounted
at an annual rate of 3.5%. Discounting is applied from the earliest
point at which a patient can enter the service in the model.Model structure
The model simulates the experience of a hypothetical birth cohort
from a normal epithelial state through to the development of
adenomatous colorectal polyps, colorectal cancer, and eventual
death. Discrete health states are modeled for low-, intermediate-,
and high-risk patients [8]. Cancer states are modeled according to
the Turnbull modification of Dukes’ staging system (Dukes’ A–C and
stage D) [9,10]. Prior to diagnosis, the model simultaneously
operates in two dimensions: 1) the patient’s true underlying
histological state, defined by the presence/absence of adenomas
and/or cancer, and 2) what is known about the given patient’s
histology at any point of interaction with the colorectal service.
Upon entry into the cancer service, patients remain notionally
within the preclinical model until they undergo some change in
clinical state (e.g., they receive a positive diagnosis of colorectal
cancer, or are identified as having adenomas) or die. A proportion of
the model population never develops adenomas or interacts with
the cancer service during their lifetime. Preclinical natural history
progression is characterized by using time-dependent Weibull
distributions to describe dwell time in each histological state. At
any point within the simulation, preclinical disease progression can
be interrupted by patient presentation and intervention or other-
cause mortality. With the exception of acute obstruction,
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evidence concerning the joint relationship between symptoms,
presentation rates, and diagnostic test operating characteristics.
Diagnosis, screening, and surveillance. The model simulates
five possible entry routes into the colorectal cancer service:
elective/emergency symptomatic presentation, referral from
elsewhere in secondary care, follow-up for screen-positives, and
surveillance for individuals in whom adenomas have previously
been found. In each instance, patients follow rule-based diag-
nostic algorithms that are dependent on sampled test operating
characteristics and probabilities of compliance, harm, and sub-
sequent mortality. The initial test outcome determines whether
the patient requires further investigation, immediate treatment
(e.g., surgery for perforation), discharge (and whether their risk
profile is subsequently modified), or referral into the colorectal
cancer treatment model. Risks of complications and mortality are
modeled for all investigations that involve bowel preparation
and/or direct endoscopic visualization (colonoscopy [COL], flexi-
ble sigmoidoscopy, computed tomography colonography [CTC],
and barium enema). COL, barium enema, and flexible sigmoido-
scopy are assumed to be used only in patients younger than 85
years. Most patients referred for diagnostic investigation undergo
COL; however, some undergo alternative tests because of the
presence of certain symptoms (e.g., palpable abdominal mass),
older age, or patient choice. Patients with acute symptoms are
assumed to undergo preoperative imaging to identify the primary
cause of the symptom secondary to the underlying tumor. A
proportion of patients with underlying colon cancer who present
with acute obstruction are assumed to undergo stenting as a
bridge to elective surgery. If stenting is clinically successful, a
lower operative mortality risk is modeled relative to those under-
going emergency surgery. Following diagnosis, patients who
survive their emergency surgery are assumed to have the same
prognosis as those who undergo elective surgery. Patients with-
out obstruction are assumed to undergo elective surgery. Unfit
patients presenting with emergency symptoms are assumed to
receive supportive care and die imminently.
The model assumes the full rollout of biennial fecal occult
blood screening for individuals aged 60 to 69 years. Some patients
are assumed to never attend screening. Of those who participate
on at least one occasion, a random proportion is assumed to
participate during each screening round. Adenomas surveillance
is modeled up to the age of 75 years [8]. While undergoing
surveillance, patients are assumed to be ineligible for screening.
Surveillance and diagnostic pathways for increased-risk groups
(hereditary nonpolyposis colorectal cancer, familial adenomatous
polyposis , ulcerative colitis, and Crohn’s disease) are not explic-
itly modeled because of 1) an absence of evidence through which
to directly parameterize or calibrate preclinical disease progres-
sion, 2) limited evidence regarding the epidemiology of these risk
factors, and 3) the computational complexity associated with
their inclusion. These patients are not excluded but are instead
subsumed within the broader heterogeneous population.
Treatment and follow-up of nonmetastatic disease. The majority
of patients with nonmetastatic colon cancer undergo active treat-
ment, with the remainder receiving supportive care. Surgery is
assumed for all fit individuals younger than 85 years; beyond this
age, 50% of the patients are assumed to undergo surgery. Adjuvant
and palliative chemotherapies are assumed to be available for
patients below 80 years of age. All fit patients with Dukes’ A colon
cancer, and a proportion of those with Dukes’ B/C disease, are
assumed to undergo surgery alone and subsequently enter follow-
up. The remainder receive surgery and adjuvant chemotherapy.
Based on clinical advice and a lack of published evidence related toparticular treatments, local relapse is not modeled for colon can-
cer patients. For rectal cancer, treatment options and prognosis
are modeled principally according to magnetic resonance
imaging–predicted circumferential resection margin involvement.
Patients for whom an R0 resection is anticipated are assumed to
undergo either short-course preoperative radiotherapy and surgery,
or initial surgery alone with selective chemoradiation (CRT) for
those with involved margins. Patients for whom an R1/R2 resection
is predicted are assumed to undergo preoperative CRT; subsequent
prognosis is modeled according to whether an R0 resection is
achieved. The rectal cancer model operates by using the same
general structure as the colon cancer model. Local relapse is
included but is assumed to result only in additional surgery;
possible relationships between local relapse incidence and distant
relapse or death are not modeled because of a lack of data to
differentiate between excess mortality resulting from local and
distant relapse. A proportion of patients is assumed to receive a
stoma, either permanent or temporary.
For all patients who survive surgery with curative intent, a
disease-free survival (DFS) interval is sampled from stage-, treat-
ment-, and location-specific parametric survival curves. From
this point, other-cause mortality and relapse are modeled as
competing risks. Patients who remain alive and disease-free 5
years following surgery are assumed to remain relapse-free
indefinitely.
Management of metastatic colorectal cancer. Patients who
present with synchronous metastatic disease and those who suffer
metastatic relapse are allocated to one of three groups: 1) initially
operable, 2) potentially operable, or 3) inoperable. Patients who are fit
and have initially operable metastases may undergo curative surgery
of the liver or lungs, assuming a staged resection of the primary
tumor and metastases. Independent risks of perioperative mortality
are assumed for each resection. DFS is modeled according to the
metastatic site. Patients who remain relapse-free 5 years postsurgery
are assumed to be cured. In the event of relapse, some patients with
liver metastases may undergo re-resection and a second DFS interval
is applied. Potentially operable patients are assumed to receive
chemotherapy for up to 3 months. Patients whose tumors express
the KRAS wild-type gene are assumed to receive cetuximab plus
either 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX) or 5-
fluorouracil, folinic acid, and irinotecan (FOLFIRI) [11]; treatment
options for patients whose tumors express the mutated version of
the KRAS gene are the same with the exclusion of cetuximab. The
probability that chemotherapy renders the tumor operable is
treatment-dependent. If downstaging is successful, metastasectomy
is assumed to be attempted; thus, patients follow the pathway
described above. A proportion of resections is assumed to be aborted
open-close operations. Excluding those receiving cetuximab, patients
for whom downstaging is unsuccessful and those for whom further
surgery is unsuccessful continue receiving the same palliative
chemotherapy regimen without the opportunity for subsequent
resection (remaining overall survival [OS] and progression-free sur-
vival [PFS] are adjusted according to previous chemotherapy treat-
ment time). Patients receiving cetuximab who are not successfully
downstaged continue receiving the same regimen without cetux-
imab. Inoperable patients are assumed to receive active palliative
chemotherapy if fit, or supportive care if unfit.
Palliative treatment of colorectal cancer and best supportive
care. Fit patients with inoperable metastases are assumed
to receive palliative chemotherapy and are assigned a time to
other-cause mortality, time to cancer-specific mortality, PFS1 on
first-line treatment, PFS2 on second-line treatment, and time
receiving supportive care (calculated as OS  [PFS1 þ PFS2]).
These durations differ between chemotherapy sequences. Unfit
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and zero PFS.
Evidence used to inform model parameters
Model parameters were informed by numerous evidence sources
including systematic reviews, randomized controlled trials,
meta-analyses, observational studies, screening pilot evalua-
tions, resource use surveys, costing studies, health valuation
studies, clinical audit, and expert opinion. Natural history param-
eters were estimated by using calibration methods. Evidence
sources were identified from a previous systematic review [12],
reviews produced within the colorectal cancer guideline develop-
ment process, and additional searches. All parameter distribu-
tions are presented in Appendix 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2013.02.012.
Baseline characteristics. Patient-specific baseline characteristics
include other-cause mortality based on life tables (http://www.
ons.gov.uk/), fitness [13], location of neoplasia [14], and the
presence of an abdominal mass [15].
Unobservable parameters relating to disease natural history
and presentation behaviors. Several model parameters cannot be
observed empirically. These include natural history progression
rates, presentation rates given the patient’s underlying histology,
and the probability that an individual who presents symptomati-
cally does so with obstructing cancer. These parameters were
estimated by calibrating the model against data on age-specific
incidence [14], Dukes’ stage distribution at diagnosis [16], stage
distribution of obstructing cancers [17], and preclinical adenoma
prevalence [18]. A random walk variant of the Metropolis-Hastings
algorithm [19] was programmed into the model and run until the
chains appeared to have converged. The algorithm was then run
for a further 17,000 iterations across two independent chains to
approximate samples from the posterior distribution (see Fig. 2)
for use in the probabilistic sensitivity analysis.
Diagnostic/screening test operating characteristics and harms.
The operating characteristics of diagnostic tests and general
practitioner consultation are modeled according to true test
sensitivity and specificity given the patient’s underlying histology
based on systematic reviews, individual population-based stud-
ies, and observational data [20–25]. The probabilities of incom-
plete tests, perforation, and death were estimated from trials and
observational studies [13,26–30].
Time-to-event estimates for DFS, OS, and PFS. DFS estimates
for adjuvant/neoadjuvant treatments were estimated by fitting
parametric survival curves to observe Kaplan-Meier curves
derived from randomized controlled trials [31–33] and observa-
tional studies [34]. The Bucher method [35] for handling indirect
comparisons was used where direct estimates were not available.
For palliative treatments, a network meta-analysis [36] was used
to estimate relative hazard ratios for different chemotherapy
sequences, assuming baseline survival models for OS and PFS
reported by Seymour et al. [37].
Probability of resectability. Modeling the comparative clinical
effectiveness of alternative downstaging treatments is difficult
because the available evidence base is largely composed of
opportunistic findings reported within case series and under-
powered phase I/II clinical trials. The probability that a patient
with metastases is resectable, potentially respectable, or unre-
sectable was taken from an observational study [38]. The modelassumes that 10% of the patients are initially operable, 13% are
potentially operable, and the remainder are inoperable. At the
time of model development, there was no comparative evidence
to suggest that the downstaging benefits of oxaliplatin are any
lower than those of cetuximab; hence, the same rate is assumed
for cetuximab-including regimens. The relative success of FOL-
FIRI compared with FOLFOX in downstaging tumors was esti-
mated from one clinical trial [39]. It should be noted that these
estimates are subject to considerable uncertainty.
Probabilities of receiving individual treatments. The probabil-
ities that patients receive particular treatments were estimated
from unpublished data from a survey [40] and expert opinion.
Health-related quality of life. The definition of different color-
ectal cancer health states was based on recent systematic
reviews [12,41]. The model includes health-related quality-of-
life (HRQOL) estimates for three general health states: no cancer,
nonmetastatic/progression-free, and metastatic postprogression.
The mean HRQOL without cancer was modeled by using the UK
population EuroQol five-dimensional questionnaire tariff
reported by Kind et al. [42]. A relative risk describing utility for
nonmetastatic/progression-free cancer states was estimated
from a longitudinal health utilities index study in long-term
cancer survivors [43]. Lower HRQOL was assumed for patients
following disease progression, based on a standard gamble study
of hypothetical states of metastatic colorectal cancer [44].
Resource use and costs. Cost parameters were derived from NHS
Reference Costs [45], the British National Formulary [46], Unit
Costs for Health and Social Care [47], previous health technology
assessment reports [48], and other literature [49–51].
Methods for using alternative economic decision rules
Table 1 shows the alternative options assessed within each
guideline topic together with a description of how the baseline
model was modified to incorporate the option. Three alternative
decision rules were used: 1) piecewise cost-utility analysis [59], 2)
Birch and Gafni’s ‘‘step in the right direction’’ approach [60], and
3) disease-level constrained maximization [1].
Piecewise cost-utility analysis [59]. Total expected system costs
and quality-adjusted life-years (QALYs) for each option within each
topic were calculated over 1,500 probabilistic samples, each of
which was composed of 300,000 simulated individuals. Incremental
cost-effectiveness ratios (ICERs) were calculated by using conven-
tional economic decision rules. Options that were subject to simple
dominance or extended dominance were ruled out of the analysis.
Birch and Gafni’s ‘‘step in the right direction’’ decision rule
[60]. The results of the piecewise economic analysis were exam-
ined to identify 1) an option that increases system QALYs and
costs compared with the current service (an investment option)
and 2) an option within a different guideline topic that produces
fewer QALYs at a lower cost than the current service (a disinvest-
ment option). The investment option and the disinvestment
option were jointly propagated through the probabilistic model
to assess whether the total system QALYs are increased and total
system costs are decreased compared against the current service.
Disease-level constrained maximization [1]. The model was
programmed such that all options within all topics could be
evaluated simultaneously. Each guideline topic (topic A, topic B
y topic N) was assigned a variable, and each topic option
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Fig. 2 – Maximum a posteriori estimates by using Metropolis-Hastings calibration. (A) Observed versus predicted colorectal
cancer incidence by age. (B) Observed versus predicted stage distribution. (C) Observed versus predicted obstructed cases by
stage. (D) Observed versus predicted adenoma prevalence by age. (E) Observed versus predicted mortality by age.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 4 2 – 5 5 3548was assigned a unique number (baseline ¼ 1, alternative 1 ¼ 2,
alternative 2 ¼ 3, etc.) to allow the events, costs, and outcomes of
multiple options to be evaluated simultaneously. For example, the
current service is represented by chromosome (A1,C1,D1,D2,E1,F1,
G1,H1,I1,J1,M1,N1), whereas a shift toward a service configuration
that includes CTC, transanal endoscopic microsurgery, preopera-
tive radiotherapy, and capecitabine followed by irinotecan is
represented by chromosome (A2,C2,D11,D21,E4,F1,G1,H1,I1,J1,
M14,N1). Sixteen thousand random service configurations were
propagated through the model to identify the configuration thatproduces the greatest QALY gain with a system cost equal to or
lower than that of the current service.Results
Conventional Piecewise Cost-Effectiveness Analysis
The Whole Disease Model was capable of evaluating 11 of the 15
guideline topics (Table 2). Topic O was excluded because the
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 4 2 – 5 5 3 549options were not fully defined. Topics B, K, and L related to
staging/imaging technologies; these were excluded from the
economic analysis because of insufficient evidence to character-
ize disease misclassification and the complexity associated with
modeling counterfactual pathways, costs, and outcomes (note
also that most ‘‘wrong’’ diagnostic classification decisions will
already be embedded within randomized controlled trial evi-
dence used to inform the model parameters).
The model suggests that CTC is expected to dominate the
other diagnostic options. In practice, however, CTC is usually
reserved for older, frail patients who cannot tolerate COL, and
this technology is not available at all NHS trusts. The second
most effective diagnostic option is flexible sigmoidoscopy-
barium enema although this offers small benefits and consid-
erable additional costs over the current baseline pathway.
With respect to topic C, transanal endoscopic microsurgery is
expected to dominate radical resection because of its lower
marginal cost and its expected improvement in both local and
distant relapse.
The economic analyses of topics D1 and D2 produce exactly
the same result, which is intuitively sensible, as CT is modeled as
a precursor to allow for the use of stenting. The incremental cost-
effectiveness ratio for stenting versus no stenting is expected to
be around £1473 per QALY gained.
For topic E, preoperative CRT is expected to be the most
effective option for resectable rectal cancer patients with an ICER
of approximately £18,084 per QALY gained as compared against
preoperative radiotherapy. Selective postoperative CRT and the
current baseline service (a mixture of pre- and postoperative
treatment) are expected to be dominated.
The analysis of topic F suggests that simultaneous resection
in patients with operable metastases may offer considerable cost
savings. There was insufficient evidence available to quantify the
mortality risk associated with staged resections; hence, this topic
was evaluated as a crude cost-minimization analysis. This is not
ideal, and further clinical evidence should be sought when this
becomes available.
Owing to overlap between guideline topics, the analysis of
topic G is a more restrictive analysis of that presented for topic E
with the exclusion of the selective postoperative CRT option. As
this decision option was dominated, the results are otherwise
identical to those for topic E.
The analysis of topic H suggests that adjuvant chemotherapy
dominates no adjuvant chemotherapy in patients with stage II/III
rectal cancer. Some caution is advised because of confounding in
the evidence used to describe the baseline relapse hazard.
The analysis of topic I suggests that adjuvant chemotherapy
for patients with Dukes’ B colon cancer is expected to dominate
no chemotherapy.
For topic J, hepatic arterial infusion is expected to be the most
effective option for patients with liver-only metastases. Chemo-
therapy is expected to produce fewer QALYs than hepatic arterial
infusion, although this difference is small. Supportive care alone
is unsurprisingly the least effective and the least expensive
option. The ICER for hepatic arterial infusion versus chemo-
therapy is expected to be around £110,932 per QALY gained,
while the ICER for chemotherapy versus best supportive care is
expected to be around £16,608 per QALY gained.
For topic M, the most effective option is expected to be
capecitabine plus oxaliplatin followed on progression by capeci-
tabine plus irinotecan. This is unlikely to be considered cost-
effective under current acceptable thresholds, as the ICER is in
excess of £134,000 per QALY gained. The ICER for capecitabine
plus oxaliplatin followed on progression by irinotecan is expected
to be around £19,160 per QALY gained as compared against first-
line capecitabine followed by rechallenging with capecitabine.
Based on the results for topics J and M, the indirect ICER for thischemotherapy option versus supportive care is expected to be
around £11,867 per QALY gained. All other options are expected
to be ruled out by simple or extended dominance.
For topic N, the current mix of intensive and relaxed follow-up
is likely to yield an ICER of £15,551 per QALY gained compared
against relaxed follow-up.
Sendi, Birch and Gafni Piecewise Investment-Disinvestment
Decision Rule
Preoperative CRT for rectal cancer is expected to produce more
QALYs at a greater cost than the current mix of adjuvant treat-
ments. Disinvestment in the existing system could be used to
fund this intervention. Joint investment in preoperative CRT and
disinvestment in palliative chemotherapy to the less expensive
and less effective capecitabine-irinotecan sequence is expected
to produce a net improvement in system QALYs together with a
reduction in the total system cost. It should be noted that this
analysis is intended only to demonstrate the use of this decision
rule, and other investment/disinvestment scenarios may produce
more net QALYs gains and/or cost savings.
Disease-Level Constrained Maximization
Figure 3 shows the results of the constrained maximization
analysis. Each plotted point represents the incremental costs
and QALY gains for each unique service configuration compared
against the current service. Assuming that system costs are
constrained at their current level, the optimal service configu-
ration is that which dominates the current service while also
producing the greatest number of QALYs. This approach directly
deals with technical efficiency and, to some degree, allocative
efficiency, albeit within the confines of the direct health benefits
generated by the colorectal cancer service. These constrained
maximization results should however be interpreted with cau-
tion because this analysis is deterministic and does not account
for the uncertainty surrounding the available evidence due to the
considerable time constraints associated with model run time.Discussion
This study demonstrates that Whole Disease Modeling is feasible
and can provide a consistent and coherent platform for the
economic evaluation of most interventions across a disease
pathway. Within this case study, the Whole Disease Model was
capable of evaluating 11 of 15 (73%) economic questions within
the colorectal cancer guideline. Some analyses were crude;
however, this reflects the uncertainty within the evidence base
rather than a limitation of the modeling approach itself. The
economic analysis of four topics was not attempted because of
the vague definition of the research question or the absence of
sufficient evidence to warrant formal evaluation. This analysis
produced a considerably larger amount of economic information
than that produced by piecewise economic analysis within the
usual guideline process. Within the colorectal cancer guideline
development process, just 1 of the 11 topics (topic M) was
subjected to formal economic evaluation. The guideline docu-
ment cites several reasons why other topics were not subjected to
economic analysis including weak data, difficulties in capturing
downstream events, costs and outcomes, and small populations
reflected in the selected topics.
The factors captured within the analysis of topic M within this
guideline analysis model and the Whole Disease Model were
broadly similar, showing that the broader boundary of a Whole
Disease Model does not restrict the level of depth possible within
the model. Both the guideline model and the Whole Disease
Model adopted similar structures: the same health states for
Table 2 – Probabilistic cost-effectiveness results for 300,000 simulated individuals.
Topic Option Cost (£) QALY Inc. cost (£) Inc. QALY ICER (QALY) (£)
Baseline service 103,857,495 14,636,083 – – Dominated
A CT colonography 97,517,419 14,636,253 1,297,809 2471.96 Dominating
FSIG-BE 107,471,657 14,636,087 – – Dominated
Baseline (COL) 103,857,495 14,636,083 – – Dominated
FSIG-COL 98,815,228 14,633,781 – – –
C TEMS 100,445,898 14,636,331 3,411,597 248.55 Dominating
Radical resection 103,857,495 14,636,083 – – –
D1 Baseline 103,857,495 14,636,083 207,617 140.94 1,473
No CT scan 103,649,878 14,635,942 – – –
D2 Baseline 103,857,495 14,636,083 207,617 140.94 1,473
No stenting 103,649,878 14,635,942 – – –
E All preop CRT 104,494,625 14,636,396 1,197,601 66.22 18,084
All preop RT 103,297,024 14,636,329 – – –
Baseline 103,857,495 14,636,083 – – Dominated
No preop adjuvant tx 104,333,702 14,635,990 – – Dominated
F Simultaneous resection 103,757,024 14,636,083 100,471 0.00 Dominating
Baseline (staged) 103,857,495 14,636,083
G All preop CRT 104,494,625 14,636,396 1,197,601 66.22 18,084
All preop RT 102,896,369 14,636,329 – – –
Baseline 103,857,495 14,636,083 – – Dominated
H Adjuvant chemotherapy 103,358,231 14,636,137 499,264 53.58 Dominating
Baseline 103,857,495 14,636,083 – – –
I Baseline 103,857,495 14,636,083 189,507 149.38 Dominating
No adjuvant chemotherapy 104,047,002 14,635,934 – – –
J HAI 106,308,256 14,636,105 2,450,761 22.09 110,932
Baseline 103,857,495 14,636,083 13,111,810 789.47 16,608
BSC only 90,745,685 14,635,293 – – –
M XELOX-XELIRI 103,548,863 14,636,163 715,860 5.31 134,938.96
XELOX-FOLFIRI 104,549,675 146,36,163 – – Dominated
FOLFOX-XELIRI 106,494,974 14,636,163 – – Dominated
FOLFOX-FOLFIRI 107,319,353 14,636,163 – – Dominated
XELOX-IRI 102,833,003 14,636,158 4,812,554 251.18 19,159.98
FOLFOX-IRI 105,779,115 14,636,158 – – Dominated
Baseline 103,857,495 14,636,083 – – Dominated
XELIRI-XELOX 105,324,882 14,636,055 – – Dominated
XELIRI-FOLFOX 106,522,006 14,636,055 – – Dominated
FOLFIRI-XELOX 108,144,085 14,636,055 – – Dominated
FOLFIRI-FOLFOX 109,163,047 14,636,055 – – Dominated
XELIRI-IRI 105,577,225 14,636,039 – – Dominated
XELIRI-XEL 104,368,886 14,636,032 – – Dominated
FOLFIRI-5-FU/FA 107,962,889 146,36,032 – – Dominated
XEL-XELOX 99,033,548 14,635,931 – – Ext dom
5-FU/FA-FOLFOX 102,913,909 14,635,930 – – Dominated
XEL-XELIRI 100,025,257 14,635,920 – – Dominated
5-FU/FA-FOLFIRI 103,711,773 14,635,919 – – Dominated
XEL-IRI 99,239,714 14,635,913 – – Dominated
5-FU/FA-IRI 102,141,844 14,635,913 – – Dominated
XEL-XEL 98,020,449 14,635,906 – – –
5-FU/FA-5-FU/FA 101,704,870 14,635,906 – – Dominated
N Baseline 103,857,495 14,636,083 1,827,129 117.49 15,551
Relaxed follow-up 102,030,367 14,635,965 – – –
BSC, best supportive care; COL, colonoscopy; CRT, chemoradiation; CT, computed tomography; ext dom, extendedly dominated; FOLFIRI, 5-FU/
FA plus irinotecan; FOLFOX, 5-FU/FA plus oxaliplatin; FSIG, flexible sigmoidoscopy; 5-FU/FA, 5-fluorouracil plus folinic acid; HAI, hepatic
arterial infusion; IRI, irinotecan; preop, preoperative; RT, radiotherapy; TEMS, transanal endoscopic microsurgery; tx, treatment; XELIRI,
capecitabine plus irinotecan; XELOX, capecitabine plus oxaliplatin.
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Fig. 3 – Results of the constrained maximization analysis. Optimal service configuration—topic A: CTC; topic C: TEMS; topic
D1: CT scan; topic D2: stenting; topic E: preoperative chemoradiation; topic F: simultaneous resection; topic G: see topic E;
topic H: adjuvant chemotherapy; topic I: adjuvant chemotherapy; topic J: palliative chemotherapy; topic M: XELOX-XELIRI;
topic N: intensive follow-up. CT, computed tomography; CTC, computed tomography colonography; QALY, quality-adjusted
life-year; TEMS, transanal endoscopic microsurgery.
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progression-free on first-line treatment, alive and progression-
free on second-line treatment, alive with disease progression
following first-line treatment, alive with disease progression
following second-line treatment, and dead). Similarly, baseline
and relative OS and PFS estimates were applied as mean sojourn
times conditional on treatment sequence. In both models, these
estimates were derived from network meta-analyses (a de novo
analysis was undertaken in the guideline model while the Whole
Disease Model instead relied on a published meta-analysis). The
cost components included in each model were also similar,
comprising drug acquisition, administration, and supportive care
costs. Two key differences between the models are noteworthy.
First, the guideline model includes utility adjustments for diar-
rhea, hand-foot syndrome, and febrile neutropenia for specific
lines of chemotherapy using data from breast cancer as a proxy.
In contrast, we did not include differential HRQOL impacts
associated with specific chemotherapy sequences as the selective
inclusion and valuation of some adverse events, but not others,
would likely bias the model results. Our view is that the existing
evidence base is simply too weak to include such health effects in
a meaningful way. Second, we included a broader set of chemo-
therapy sequences than the guideline model. In both analyses,
the majority of possible sequences were ruled out by simple or
extended dominance. The preferred option in both analyses,
assuming a threshold of £20,000 per QALY gained, involves first-
line combination therapy using oxaliplatin followed by second-
line irinotecan. The guideline model suggests that first-line
treatment should include 5-FU/FA while the Whole Disease Model
suggests that this combination should instead use capecitabine.
This conflict is likely to be largely driven by different assump-
tions regarding the adverse event profiles for these two drugs.
While this article highlights that Whole Disease Models can
provide considerably more useful economic information than the
conventional piecewise analyses, other benefits should also be
acknowledged. First, a broader value of Whole Disease Modelingis not just that it can evaluate a wealth of decision alternatives at
various points in a disease pathway, but also that it does so
within a single consistent set of assumptions about the disease
and its management. Given the model scope, other economic
questions beyond the remit of the guideline, for example, those
questions posed within NICE’s Technology Appraisal Programme,
could also be addressed by using the same model infrastructure.
As such, this modeling approach could be used as a means of
bringing consistency between individual colorectal appraisals,
clinical guidelines, and other policy decision problems. Further-
more, by placing decision nodes at various points in the simu-
lated disease and treatment pathways, the model can also
address questions about multiple changes to the entire pathway
within a framework that explicitly considers the opportunity
costs of service investment. This is essentially the question being
asked within clinical guidelines, but remains one that conven-
tional piecewise economic evaluation simply cannot answer.
Further developmental work around operationalizing such deci-
sion approaches may be valuable.
These benefits carry several costs that in some circumstances
may preclude the development of Whole Disease Models. First,
model development requires a nontrivial investment of time and
resource. The development and analysis of the colorectal cancer
Whole Disease Model presented here required approximately 12
months. All model development was undertaken by one individ-
ual, although the authors did have access to evidence reviews
undertaken by the NICE GDG. In addition, the need to capture the
depth of the pathways and the presence of complicated feedback
loops and differential prognoses for specific patient subgroups
almost inevitably requires a simulation modeling approach,
while the need to capture interactions between unobservable
natural history and diagnostic/screening processes necessarily
requires some form of model calibration. The combination of
these two factors has significant implications for the time and
technical complexity associated with model development.
Despite these concerns, it is reasonable to argue that the time
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 4 2 – 5 5 3552and resource costs of undertaking 11 analyses by using a single
Whole Disease Model are likely to be markedly less than those
associated with developing 11 de novo piecewise models. Prag-
matically, it may be possible to adopt some of the system-level
ideas presented here within a more restrictive model boundary;
however, this will infringe the range of economic questions that
the model can be used to address.
So, what might this mean for the process of clinical guideline
development? This case study suggests that Whole Disease
Models could be considerably more useful than conventional
piecewise economic evaluation. However, this represents a single
example of a Whole Disease Model—in some clinical areas,
Whole Disease Model development may require more time while
others will require less. While Whole Disease Modeling is tech-
nically difficult, time-consuming, and resource-intensive, the
benefits of producing economically informed guideline recom-
mendations may far outweigh the costs of generating them by
using this approach. There are other examples of system-level
models available in the literature that in principle could be used
in informing the economic basis of clinical guidelines; the most
pertinent examples are the Coronary Heart Disease Policy model
[61] and the Archimedes Diabetes model [62]. These models are
also technically complex in nature and required considerable
model development time. The alternative is however to continue
to rely on a small number of de novo piecewise models developed
within the guideline process, and, where possible, to fill in the
gaps by using published economic analyses. In most disease
areas, numerous gaps will likely remain whereby recommenda-
tions are formed on the basis of analyses that have a dubious
applicability to the specified guideline question, or, in some
instances, no economic evidence whatsoever. If we truly believe
that the basis of resource allocation decisions should be an
economic one, then this position is far from optimal. Whole
Disease Modeling may represent a more useful basis for inform-
ing these decisions. Future research should focus on the feasi-
bility of developing and using Whole Disease Models within live
guideline development processes. This should be considered a
priority for joint working between guideline developers, model
developers, and other stakeholders to the clinical guideline
development process.
Conclusions
This study demonstrates that Whole Disease Modeling can allow
for the economic analysis of most interventions across a disease
service within a consistent conceptual and mathematical infra-
structure. The approach may be especially valuable in informing
clinical guideline development.
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